Related Experiment Video
Updated: May 4, 2026

Identifying the Effects of BRCA1 Mutations on Homologous Recombination using Cells that Express Endogenous Wild-type BRCA1
Published on: February 17, 2011
Genetic evidence supporting potential causal roles of EIF4 family in breast cancer: a two-sample randomized Mendelian
Jin-Yu Shi1,2, Rui Wen3, Jin-Yi Chen4
1Department of Breast Surgery, Shanxi Provincial People's Hospital, Taiyuan, 030000, Shanxi, China.
Abstract:
Translational control plays a crucial role in the regulation of apoptosis, with the EIF4 family serving as one of the mRNA translation factors that modulate the process of mRNA translation based on mRNA characteristics. To address this potential causal role of EIF4 family proteins and breast cancer, Mendelian randomization was employed. The study incorporated four sets of genetics instrumental variables, namely EIF4E, EIF4B, EIF4A, and EIF4EBP2. The outcome variables selected for analysis were the BCAC consortium, which included estrogen receptor positive (ER+) and estrogen receptor negative (ER-) samples. To assess the potential violations of the MR assumption, the primary MR analysis employed inverse variance weighted (IVW), and several sensitivity analyses were conducted. The findings of the two-sample MR analysis indicate that EIF4E has an adverse effect on breast cancer risk (p = 0.028). However, the evidence for the relationship between EIF4E and ER status of breast cancer suggests a weak association with ER+ breast cancer (p = 0.054), but not with ER- breast cancer (p > 0.05). The study findings indicate that EIF4A is not causally linked to the risk of ER+ breast cancer, but is significantly associated with an elevated risk of ER- breast cancer (p = 0.028). However, the evidence is inadequate to support the effects of EIF4B and EIF4EBP2 on breast cancer (p > 0.05). Our results suggest that EIF4 may be a potential factor in the occurrence and development of breast cancer, which may lead to a better understanding of its causes and prevention.
Insights
The EIF4 family of proteins influences breast cancer risk. EIF4E is linked to increased breast cancer risk, while EIF4A is associated with estrogen receptor-negative breast cancer.
Area of Science:
- Genetics
- Oncology
- Molecular Biology
Background:
- Translational control is vital for apoptosis regulation.
- The EIF4 family of proteins modulates mRNA translation.
- Understanding the role of EIF4 proteins in breast cancer is crucial.
Purpose of the Study:
- To investigate the potential causal relationship between EIF4 family proteins and breast cancer risk.
- To examine the association of EIF4 proteins with estrogen receptor-positive (ER+) and estrogen receptor-negative (ER-) breast cancer subtypes.
Main Methods:
- A two-sample Mendelian randomization (MR) study was conducted.
- Genetic instrumental variables for EIF4E, EIF4B, EIF4A, and EIF4EBP2 were used.
- The BCAC consortium data, including ER+ and ER- samples, served as outcome variables. Inverse variance weighted (IVW) and sensitivity analyses were performed.
Main Results:
- EIF4E showed an adverse effect on overall breast cancer risk (p=0.028).
- EIF4A was significantly associated with an elevated risk of ER- breast cancer (p=0.028) but not ER+ breast cancer.
- No significant causal links were found for EIF4B and EIF4EBP2 with breast cancer risk.
Conclusions:
- EIF4 family proteins may play a role in breast cancer development.
- EIF4E and EIF4A show specific associations with breast cancer risk and subtypes.
- Further research into EIF4's role could inform breast cancer prevention strategies.
More Related Videos
08:15gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair
Published on: October 6, 2014
11:12Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
Published on: August 1, 2018
Related Concept Videos
Mitogens and the Cell Cycle
Cancer Prevention
Some...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase